Thiosulfate-enhanced kidney preservation for deceased-donor transplants
Official title: Evaluation of Thiosulfate Enhanced Organ Preservation Solution in Kidney Transplantation
Run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · NCT06288152 · Data updated 2026-11-12
This trial will test whether adding sodium thiosulfate to the solution used to preserve deceased-donor kidneys helps reduce transplant-related injury and improve early kidney function in adults with end-stage renal disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Academic / other |
| Locations | 1 site (London, Ontario) |
| Status | Recruiting |
| Started | May 3, 2025 |
| Main results expected | March 1, 2027 |
| Study ends | March 1, 2027 |
| Registry record updated | April 13, 2026 |
| Trial ID | NCT06288152 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with end-stage renal disease who are receiving a deceased-donor kidney (NDD or DCD), can give informed consent, and are not undergoing multi-organ or living-donor transplant are eligible.
✕Probably not a fit
Living-donor recipients, multi-organ transplant patients, pregnant individuals, and people with known allergy to the study medication are excluded and would not be candidates for benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study adds sodium thiosulfate to the cold preservation solution for kidneys recovered from deceased donors (NDD or DCD) and transplanted into adult recipients. Eligible participants are adults with end-stage renal disease receiving a deceased-donor kidney at London Health Sciences Centre. The trial compares treated grafts to standard preservation with outcomes such as delayed graft function, markers of ischemia-reperfusion injury, and early graft function monitored after transplantation. Study procedures focus on the preservation and transplantation period with follow-up to record kidney function and safety events.
Why it matters
Potential benefit: If successful, this approach could lower rates of delayed graft function, reduce ischemic injury, and improve early graft survival after deceased-donor kidney transplantation.
How similar studies have gone: Antioxidant and preservation-enhancement strategies have shown promise in preclinical models and limited clinical settings, but adding sodium thiosulfate directly to organ preservation solution for kidney transplants is relatively novel and not yet proven in large trials.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age and over * End-Stage Renal Disease * Receiving a kidney transplant from a deceased donor (NDD or DCD) Exclusion Criteria: * Under 18 years of age * Inability to provide informed consent * Living donor kidney recipients * Pregnant individuals * Known allergy to study medication or its components (non-medicinal ingredients) * Multiorgan transplant patients such as simultaneous kidney pancreas or liver kidney transplants * Currently enrolled in another interventional transplant clinical trial, or another clinical trial that in the opinion of the QI and PI would greatly impact the results of this study.
Where it's running
-
London Health Sciences Centre
London, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Alp Sener — Principal Investigator
- Study coordinator: Cadence Baker
- Email: cadence.baker@lhsc.on.ca
- Phone: 519-685-8500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of general vs spinal-epidural anesthesia on kidney transplant biomarkers
This study tests whether sevoflurane general anesthesia or combined spinal-epidural anesthesia changes markers of cellular stress and protective peptides in adults undergoing kidney transplantation.
-
Omnisol-preserved kidneys before transplant (hypothermic machine perfusion)
This study tests whether using Omnisol during hypothermic machine perfusion before kidney transplant can improve early graft function compared with standard preservation.
-
How Propofol and Sevoflurane Affect miRNA in Living Kidney Donors
This study tests whether using propofol or sevoflurane during donor nephrectomy changes levels of miRNAs in living kidney donors.
-
How kidney transplant patients feel about using artificial intelligence in medicine
This international survey asks adults who have had a kidney transplant how they feel about AI tools that predict graft loss and what it might mean for their daily care.
-
Personalized therapeutic stories for children after kidney transplant.
We will test whether clinician-supervised AI can create age-appropriate, personalized therapeutic stories for children aged 5–12 who have received a kidney transplant and their families.
-
Treating blood vessel problems after a kidney transplant
This effort will try catheter-based angioplasty and advanced imaging to see if they help kidney transplant recipients with graft dysfunction or stubborn high blood pressure from possible transplant blood‑vessel problems.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.